Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 13Thoracic 5Gynecologic 4Breast 3Head & Neck 2Genitourinary 2Dermatologic 2Lymphoid 1

Conditions

Urinary Bladder Neoplasms 30Carcinoma, Renal Cell 17Prostatic Neoplasms 13Carcinoma, Transitional Cell 11Melanoma 8Carcinoma, Non-Small-Cell Lung 7Breast Neoplasms 7Uterine Cervical Neoplasms 6Kidney Neoplasms 6Non-Muscle Invasive Bladder Neoplasms 5Triple Negative Breast Neoplasms 4Small Cell Lung Carcinoma 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Neoplasm Metastasis 4Colorectal Neoplasms 4Carcinoma, Merkel Cell 4Squamous Cell Carcinoma of Head and Neck 3Head and Neck Neoplasms 3Carcinoma, Hepatocellular 3Urothelial Cancer 2Testicular Neoplasms 2Stomach Neoplasms 2Neoplasms 2Lung Neoplasms 2Hodgkin Disease 2Esophageal Neoplasms 2Endometrial Neoplasms 2Carcinoma in Situ 2Carcinoma 2

Interventions

pembrolizumab 35Nivolumab 14Docetaxel 11atezolizumab 10Paclitaxel 9Carboplatin 7Gemcitabine 6Cisplatin 6Trastuzumab 5Magnetic Resonance Spectroscopy 5Ipilimumab 5Fluorodeoxyglucose F18 5Cyclophosphamide 5Bevacizumab 5fludarabine 4avelumab 4Specimen Handling 4Psychiatric Rehabilitation 4Oxaliplatin 4Leucovorin 4Fluorouracil 4Albumin-Bound Paclitaxel 4130-nm albumin-bound paclitaxel 4cemiplimab 3Taxes 3Polymerase Chain Reaction 3Pemetrexed 3Irinotecan 3Gene Expression Profiling 3Early Intervention, Educational 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Stomach Neoplasms × durvalumab × Genitourinary × Clear all
NCT03228667 2026-01-14

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

ImmunityBio, Inc.

Phase 2 Active not recruiting
40 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT03544723 2020-06-09

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

MultiVir, Inc.

Phase 2 Unknown
40 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicLymphoidThoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Hodgkin Disease, Liver Neoplasms, Lymphoma, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡